SCHEMBL13633829

SCHEMBL13633829

COc1ccc(S(=O)(=O)n2nc(C)cc2C)cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.63
ALDH1A1 P00352 4/20 0.61
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
PKM P14618 1/20 0.61
TSHR P16473 4/20 0.59
MAPK1 P28482 3/20 0.59
MAPT P10636 3/20 0.59
HPGD P15428 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
USP2 O75604 1/20 0.58
HSD17B10 Q99714 1/20 0.58
HTT P42858 1/20 0.57
PARP1 P09874 1/20 0.57
THRB P10828 1/20 0.53
POLB P06746 2/20 0.52
LMNA P02545 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4184681 0.71 GPBAR1 (0.90) GAAALDH1A1PKMTSHRMAPK1
SCHEMBL3830421 0.71 GPBAR1 (0.90) GAAALDH1A1PKMTSHRMAPK1
SCHEMBL3830418 0.71 GPBAR1 (0.64) ALDH1A1PKMTSHRMAPK1MAPT
SCHEMBL8602385 0.70 PDE4A (0.63) ALDH1A1TSHRMAPK1MAPTSMN1; SMN2
SCHEMBL22494200 0.69 TSHR (0.62) GAAALDH1A1MEN1KMT2ATSHR
SCHEMBL7209087 0.69 GPBAR1 (0.91) ALDH1A1MEN1KMT2APKMTSHR
SCHEMBL6367892 0.69 GPBAR1 (0.97) ALDH1A1PKMTSHRMAPK1MAPT
SCHEMBL20758417 0.68 POLB (0.71) GAAALDH1A1KMT2APKMTSHR
SCHEMBL7358967 0.68 PDE4A (0.75) ALDH1A1MEN1KMT2ATSHRMAPK1
SCHEMBL862980 0.68 POLB (0.73) TSHRMAPK1SMN1; SMN2HTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A GAA 77/4885ALDH1A1 802/4885MEN1 2737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.